Biocon gets license for Adagio Therapeutics’ ADG20 for Covid-19 treatment
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing an antibody treatment based on ADG20 for India and certain emerging markets. ADG20 is a novel monoclonal antibody that targets the spike protein of SARS-CoV-2 and related coronaviruses. It is […]